Crovalimab is under clinical development by Chugai Pharmaceutical and currently in Phase II for Sickle Cell Disease With Vaso-Occlusive Crisis. According to GlobalData, Phase II drugs for Sickle Cell Disease With Vaso-Occlusive Crisis have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Crovalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Crovalimab overview

Crovalimab (Piasky) is an anti-complement C5 recycling antibody. It is formulated as solution for subcutaneous route of administration. It is indicated for use in adults and adolescents (≥12 years old) with paroxysmal nocturnal hemoglobinuria who have not received complement inhibitor therapy.

Crovalimab (RO-7112689, RG-6107, SKY-59) is under development for the treatment of vaso-occlusive crisis associated with sickle cell disease, paroxysmal nocturnal hemoglobinuria, lupus nephritis and atypical hemolytic uremic syndrome (aHUS). The drug candidate is administered through the intravenous and subcutaneous route as a solution. The drug candidate is a monoclonal antibody which acts by targeting C5 which  is developed based on recycling antibody technology. It is a new molecular entity (NME).

It was also under development for the treatment of Guillain-Barre syndrome.

Chugai Pharmaceutical overview

Chugai Pharmaceutical (Chugai), a subsidiary of F. Hoffmann-La Roche Ltd, is focused on the research, development, commercialization, manufacturing, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. The company is operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

For a complete picture of Crovalimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.